Kareva, Lidija

Preferred name

Kareva, Lidija

Official Name

Kareva, Lidija

Main Affiliation

lidija.kareva@medf.ukim.edu.mk

Now showing 1 - 10 of 13

Some of the metrics are blocked by your
consent settings
Adverse Reactions to Intravenous Immunoglobulins - Our Experience
(ID-Design/Scientific foundation SPIROSKI, 2018-12-20)
;
;
;
Arjeta Hasani
Some of the metrics are blocked by your
consent settings
Values of lymphocyte subpopulations in healthy Macedonian children under the age of five
(International Medical Association Bulgaria (IMAB) / Peytchinski Publishing Ltd., 2016-12)
;
;
Background: The effects of demographic factors on a wide range of immunological variables demonstrate the importance of having normative data representative of particular patient population. There was no lymphocyte subpopulation data for Macedonian children and the purpose of this study was to establish such a data. Subject and methods: The study population consists of 87 healthy children. Subjects were grouped into four age categories as follows: group 1 age range 5d-10d (n=15); group 2 age range 1 mo-1 yr (n=18); group 3 age 1yr-2 yr(n=20) and group 4 age 2yr-5 yr(n=34 Monoclonal antibodies labeled with fluorochromes and immunofluorescent microscopy were used to detect cells bearing specific cell markers. Results: The mean lymphocyte cell count gradually fell with increasing age from 6,65x10^9/l in group 1, to 5,67x10^9/l in group 2, 4,55x10^9/l in group 3, and to 4,14x10^9/l in group 4. Absolute values of CD3, CD4 and CD20 positive cells decreased gradually with age. Significant differences in mean absolute values were observed for absolute lymphocyte counts between groups 1/2 and 1/4 (P<0,01) and groups 2/4(P<0,05); for CD3 positive lymphocytes between groups 1/3(P<0,05) and 1/4(P<0,01); for CD4 positive lymphocytes between groups 1/3 (P<0,05) and 1/4(P<0,01) and for CD20 positive lymphocytes between groups 1/3 and 3/4(P<0,05) and groups 1/4 (P<0,01). Significant difference for CD4/CD8 ratio and for percentage values of different lymphocyte subpopulations between the different age groups was not found. Conclusion: This data may serve as a reference range for studies of Macedonian pediatric subjects.
Some of the metrics are blocked by your
consent settings
Sindroma inflamatore multisistemike te femijet e asocuar me SARS-Covid 2 – karakteristikat klinike dhe trajtimi.
(Medicus 2021, Vol. 26 (3): 330-338., 2021-12)
A. Hasani
;
;
;
Hyrje: Sindroma multisistemike inflamatore tek femijet (MIS-c) eshte gjendje e rralle por serioze e cila lidhet me infekcionin SARS-COVID-2. Qellimi i ketij punimi eshte publikimi i pervojes tone me femije me MIS. Pershkrimi i simptomeve klinike, analizave laboratorike, mikrobiologjike dhe trajtimit do te sherbej ne rritjen e njohurive per kete syndrome te re tek femijet. Rezultatet: Jane pershkruar simptomet, shenjat klinike, analizat laboratorike dhe mikrobiologjike ne 18 femije te hospitalizuar ne repartin e Imunologjise ne periudhen dhjetor 2020-shtaror 2021. Te gjithe femijet jane pranuar ne repart me vlera te larte te parametrave inflamator, me temperature te larte minimum 3 dite para pranimit si dhe analiza serologjike pozitive per SARS-COVID2 infekcion. Ne asnje femije nuk eshte izoluar patogjen mikrobiologjik si shkaktar i mundshem etiologjik. Simptomet me te shpeshta ishin ato te traktit gastrointestinal ne 88.8% te femijeve. Ndryshimet ne lekure, edeme dhe hipotensioni ishin te pranishem ne 61.1% te rasteve. 4 femije (22.2%) ishin me simptome e shenja te apendicitit akut, tre prej te cileve jane operuar, nje eshte trajtuar ne menyre konzervative. 3 femije ishin me miokardit/perikardit dhe me pankreatit akut. Vetem nje femije (5.5%) ishte me shenja te insuficiences akute renale. Perfundimi: Femijet me MIS mund te kerkojne trajtim intenziv pediatric dhe qasje multidiciplinare ne trajtim.Njohja dhe identifikimi I hershem I kesaj gjendje si dhe udhezimi ne kohe per trajtim specialistik eshte me rendesi te veqante.
Some of the metrics are blocked by your
consent settings
Genetic and demographic features of X-linked agammaglobulinemia in Eastern and Central Europe: a cohort study
(Elsevier BV, 2009-06)
Tóth, Beáta
;
Volokha, Alla
;
Mihas, Alexander
;
Pac, Malgorzata
;
Bernatowska, Ewa
Primary immunodeficiency disorders are a recognized public health problem worldwide. The prototype of these conditions is X-linked agammaglobulinemia (XLA) or Bruton's disease. XLA is caused by mutations in Bruton's tyrosine kinase gene (BTK), preventing B cell development and resulting in the almost total absence of serum immunoglobulins. The genetic profile and prevalence of XLA have not previously been studied in Eastern and Central European (ECE) countries. We studied the genetic and demographic features of XLA in Belarus, Croatia Hungary, Poland, Republic of Macedonia, Romania, Russia, Serbia, Slovenia, and Ukraine. We collected clinical, immunological, and genetic information for 122 patients from 109 families. The BTK gene was sequenced from the genomic DNA of patients with a high susceptibility to infection, almost no CD19(+) peripheral blood B cells, and low or undetectable levels of serum immunoglobulins M, G, and A, compatible with a clinical and immunological diagnosis of XLA. BTK sequence analysis revealed 98 different mutations, 46 of which are reported for the first time here. The mutations included single nucleotide changes in the coding exons (35 missense and 17 nonsense), 23 splicing defects, 13 small deletions, 7 large deletions, and 3 insertions. The mutations were scattered throughout the BTK gene and most frequently concerned the SH1 domain; no missense mutation was detected in the SH3 domain. The prevalence of XLA in ECE countries (total population 145,530,870) was found to be 1 per 1,399,000 individuals. This report provides the first comprehensive overview of the molecular genetic and demographic features of XLA in Eastern and Central Europe.
Some of the metrics are blocked by your
consent settings
Kwashiorkor from dietary restriction secondary to cow's milk allergy
(SHMSHM/AAMD, 2020)
;
;
;
Hasani A
;
Bojadzieva S
Some of the metrics are blocked by your
consent settings
A novel mutation in SLC39A7 identified in a patient with autosomal recessive agammaglobulinemia: The impact of the J Project
(Wiley, 2022-06)
Erdős, Melinda
;
;
;
;
Hasani, Arijeta
Some of the metrics are blocked by your
consent settings
Staphylococcal Scalded Skin Syndrome
(International Medical Association Bulgaria (IMAB) / Peytchinski Publishing Ltd., 2019-08)
;
;
;
Hasani Arijeta
Staphylococcal scalded skin syndrome (SSSS) is skin disease which primarily affects children from newborns up to 5 years of age. When occurring in adults it is accompanied by immunodeficiency. In children, SSSS is usually with good prognosis and resolves with treatment completely, with low mortality, while in adults regarding underline disease mortality is up to 50%. Differential diagnosis includes Steven-Johnson syndrome, Epidermolysis bullosa (EB) and toxic epidermal necrolysis. In this article, we present 8 months old infant with SSSS caused by Staphylococcus aureus strain sensitive to penicillinases. Therapeutic and diagnostic challenges are discussed, together with differential diagnosis and therapy. Successful results are achieved in our case due to the good response to antibiotic and rigorous wound treatment in sterile conditions.
Some of the metrics are blocked by your
consent settings
Complete Kawasaki Disease in a Child with Transient Hypogammaglobulinemia of Infancy
(Македонско лекарско друштво = Macedonian medical association, 2021-10)
;
;
;
Hasani, Arjeta
Kawasaki disease is an acute febrile illness of early childhood characterized by vasculitis of the arteries. The diagnosis of complete Kawasaki disease should be made in a child who has a fever lasting 5 days or more and has at least 4 of 5 clinical criteria: rash, conjunctival injection, oropharyngeal erythema, swelling and erythema of the extremities, and unilateral cervical lymphadenopathy. Incomplete form of the disease is diagnosed when a patient presents with fever for 5 days or longer, 2 or 3 of the principal clinical features, and laboratory findings suggestive of the disease or echocardiographic abnormalities. Kawasaki disease has been described as a complication of various primary and secondary immunodeficiency disorders thus supporting an infectious etiology of this disease. Immunodeficiencies may result in an incomplete clinical presentation of Kawasaki disease and end up with delay in diagnosis and therefore treatment, which may lead to development of coronary artery aneurism . We are presenting a 2,5 year old girl with transient hypogammaglobulinemia of infancy who has complete form of the disease without coronary artery aneurism development , to emphasize the occurrence of Kawasaki disease in immune deficiency situations.
Some of the metrics are blocked by your
consent settings
Serum vitamin A and retinol binding protein in children with acute respiratory infections
(Publishing house of University School of Medicine, Pleven, Bulgaria, 2001)
;
Peova, Sonja
;
;
;
Some of the metrics are blocked by your
consent settings
Cryopyrin-Associated Periodic Syndromes and Treatment Options
(Scientific foundation Spiroski, 2020-09-03)
;
;
Cryopyrin-associated periodic syndromes (CAPSs) are a growing family of autoinflammatory diseases, also known as periodic fever syndromes. There are three forms of CAPS: (1) Familial Cold autoinflammatory syndrome or familial cold urticaria, (2) Muckle-wells syndrome, and (3) neonatal-onset multisystem inflammatory disease or chronic infantile neurological cutaneous articular syndrome. Genetic mutations in the NLRP3 gene were found to be present in most patients. The foremost common findings between all the CAPS disorders are rash, fever which is sometimes present at birth or in early childhood, joint problems, and conjunctivitis. More extreme forms of CAPS include more persistent inflammation that can cause hearing loss and meningitis and can lead to mental and developmental delays. Drugs for CAPS target the source of inflammation – which is the over-production of interleukin 1ß by modified cryopyrin inflammasomes. Three drugs are used to treat CAPS: Rilonacept, canakinumab, and anakirna. With these drugs, the prognosis is greatly improved, with most patients having less frequent episodes, decreased buildup of amyloid in the body, and extended life of severe cases up to adulthood.

Kareva, Lidija

Filters

Settings

Sort By

Results per page